Pharmaceutical composition for prevention or treatment of cardiac failure

A pharmaceutical composition, a technology for heart failure, applied in the directions of pharmaceutical combinations, pharmaceutical formulations, active ingredients of heterocyclic compounds, etc., can solve problems such as pleural effusion and cardiac hypertrophy

Inactive Publication Date: 2009-02-18
DAIICHI SANKYO CO LTD
View PDF15 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is well known that when drugs for improving insulin resistance are used clinically, harmful phenomena such as hear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for prevention or treatment of cardiac failure
  • Pharmaceutical composition for prevention or treatment of cardiac failure
  • Pharmaceutical composition for prevention or treatment of cardiac failure

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0136] Inhibitory Effects of Carbohydrase Inhibitors on Left Ventricular Hypertrophy

[0137] (1) Animals used

[0138] Rats (Wister, male, nine weeks at the time of use, sold by Japan SLC Co., Ltd.)

[0139] (2) Experimental methods and results

[0140] After anesthesia with pentobarbital (50 mg / kg i.p.), a median incision was made, and the abdominal aorta between the left and right renal arteries was dissected. A 22G injection needle was used to block along the artery, and the injection needle and the artery were ligated with silk thread. Afterwards, the injection needle was pulled out to complete the stenosis of the abdominal aorta, and then the abdomen was closed. In the sham group, the abdomen was closed without ligation. In a powder feed (FR-2 powder feed, manufactured by Funabashi Farm Co., Ltd.), compound A at a concentration of 300 ppm (w / w) and voglibose at a concentration of 20 ppm (w / w) were mixed, resulting in From the second day to the 23rd day of the narrow...

experiment example 2

[0145] Inhibitory Effects of Carbohydrase Inhibitors on Cardiac Hypertrophy Induced by Administering Drugs for Improving Insulin Resistance

[0146] (1) Animals used

[0147] Diabetic mice (BKS.Cg-+Lepr[db] / +Lepr[db] / Jcl, female, 7 weeks at the time of use, sold by Nippon Clear Co., Ltd.)

[0148] (2) Experimental methods and results

[0149] The mice were divided into groups based on blood sugar levels and body weights, and the control group was allowed to freely ingest a powder feed (FR-2 powder feed, manufactured by Funabashi Farm Co., Ltd.) for two weeks. The pioglitazone group and the combined use group were put into the powder feed mixed with pioglitazone at a concentration of 30ppm, and the compound A group and the combined use group were given compound A mixed with 100ppm concentration (w / w) in the powder feed. mixed feed. Blood glucose levels and ventricular muscle weights were measured two weeks after the start of compound administration. Blood was collected from...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is a pharmaceutical composition effective for preventing and treating cardiac failure. Specifically disclosed is a pharmaceutical composition containing a carbohydrate degrading enzyme inhibitor as an active ingredient.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing a carbohydrase inhibitor as an active ingredient and used for the prevention or treatment of heart failure. [0002] In particular, the present invention relates to the use of the above-mentioned compound in the manufacture of the above-mentioned medicine, or a method for preventing or treating the above-mentioned disease in which the above-mentioned medicine is administered to a warm-blooded animal (preferably human). Background technique [0003] Heart failure is a general term for a decline in cardiac function and a state in which blood circulation in the whole body deteriorates due to the decline in cardiac function. [0004] For the decline in cardiac output caused by chronic mechanical loads imposed on the heart by high blood pressure, the heart uses compensatory mechanisms such as ventricular enlargement, hypertrophic morphological changes, and hyperactivity of sympathetic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/13A61K31/192A61K31/255A61K31/421A61K31/426A61K31/427A61K31/445A61K31/454A61K31/7008A61K31/7034A61K31/7036A61K31/7056A61P9/00A61P9/04
CPCA61K31/351A61P9/00A61P9/04
Inventor 泉正宪松村庆子
Owner DAIICHI SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap